The most common somatic aberrations in lung adenocarcinoma are recurrent mutations in the RTK [including epidermal growth factor receptor (EGFR)]/RAS/RAF pathways, which occurred in 76% of cases (Cancer Genome Atlas Research, 2014). This evidence concerns the gene EGFR and lung adenocarcinoma.